Galapagos NV (GLPG)
Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell
€26.92
Buy
€27.44
€-0.34 (-1.23%)
Prices updated at 12 Dec 2025, 16:35 CET
| Prices minimum 15 mins delay
Prices in EUR
Galapagos NV is a clinical-stage biotechnology company. It is engaged in the discovery and development of small molecule medicines which address unmet medical conditions.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Profit margins
Valuation
Profit margins data table
Year | Gross margin (%) |
|---|---|
| 2024 | 87.35 |
| 2023 | 100.00 |
| 2022 | 100.00 |
| 2021 | - |
| 2020 | 100.00 |
| 2019 | 100.00 |
| 2018 | - |
| 2017 | - |
| 2016 | - |
| 2015 | - |
Valuation data table
Year | Price / Sales |
|---|---|
| 2025 | 6.25 |
| 2024 | 6.71 |
| 2023 | 4.40 |
| 2022 | 4.71 |
| 2021 | 6.80 |
| 2020 | 11.64 |
| 2019 | 12.75 |
| 2018 | 18.62 |
| 2017 | 24.64 |
| 2016 | 48.00 |
| 2015 | 36.60 |
Price/Forward earnings (YTD)
-18.69
Returns
Debt profile
Returns data table
Year | Return on assets (%) |
|---|---|
| 2024 | 1.74 |
| 2023 | 4.66 |
| 2022 | -4.39 |
| 2021 | -1.89 |
| 2020 | -5.18 |
| 2019 | 3.99 |
| 2018 | -2.15 |
| 2017 | -9.77 |
| 2016 | 7.08 |
| 2015 | -33.22 |
Debt profile data table
| Year | Financial leverage |
|---|---|
| 2024 | 1.43 |
| 2023 | 1.56 |
| 2022 | 1.87 |
| 2021 | 1.96 |
| 2020 | 2.14 |
| 2019 | 2.11 |
| 2018 | 1.19 |
| 2017 | 1.27 |
| 2016 | 1.43 |
| 2015 | 1.21 |
The figures shown in the Profit Margins table EBITDA column are quoted in the currency of the stock selected.
